The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Subscribe To Our Newsletter & Stay Updated
